Can we prevent or treat renal dysfunction in acute heart failure?

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 291-303

  Lazzarini, Valentina ^a   Bettari, Luca ^a   Bugatti, Silvia ^a   Carubelli, Valentina ^a   Lombardi, Carlo ^a   Metra, Marco ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Cardiorenal syndrome

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; DRONEDARONE; ENALAPRIL; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; NAXIFYLLINE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; RELAXIN; RENIN INHIBITOR; ROLOFYLLINE; TOLVAPTAN; TRIMETHOPRIM; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; ADD ON THERAPY; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DETERIORATION; DISEASE COURSE; DRUG MEGADOSE; HEART FAILURE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SIDE EFFECT; WORSENING RENAL FUNCTION;

ACUTE DISEASE; ADENOSINE; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; DIURETICS; DOPAMINE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY DISEASES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; VASODILATOR AGENTS; VASOPRESSINS;

EID: 84862581290     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9253-3     Document Type: Review

References (106)

1. Bock JS, Gottlieb SS (2010) Cardiorenal syndrome: new perspectives. Circ 121: 2592-2600
2. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P (2010) Acute dialysis quality initiative (ADQI) consensus group. Cardiorenal syndromes: an executive summary from the consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 165: 54-67(Epub 2010 Apr 20)
3. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J (2007) High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 13: 422-430
4. Metra M, Zacà V, Parati G, Agostoni P, Bonadies M, Ciccone M, Cas AD, Iacoviello M, Lagioia R, Lombardi C, Maio R, Magrì D, Musca G, Padeletti M, Perticone F, Pezzali N, Piepoli M, Sciacqua A, Zanolla L, Nodari S, Filardi PP, Dei Cas L (2011) Heart failure study group of the Italian society of cardiology. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 12(2): 76-84
5. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Card Fail 12: 257-262
6. Klein L, Massie BM, Leimberger JD, O'Connor CM, Pina IL, Adams KF, Califf RM, Gheorghiade M for the OPTIME CHF Investigators (2008) Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail 1: 25-33
7. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43: 61-67
8. Butler J, Chirovsky D, Phatak H, McNeill A, Cody R (2010) Renal function, health outcomes, and resource utilization in acute heart failure: a systematic review. Circ Heart Fail 3: 726-745
9. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL (2007) Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 13(8)599-608
10. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B (2006) Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 27: 1216-1222
11. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, Fontanella B, Lombardi C, Milani P, Verzura G, Cotter G, Dittrich H, Massie BM, Dei Cas L (2008) Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 10: 188-195
12. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI (2000) Correlates and impact on outcomes of worsening renal function in patients[65 years of age with heart failure. Am J Cardiol 85: 1110-1113
13. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, Krumholz HM (2003) Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 9: 13-25
14. Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 94: 957-960
15. Logeart D, Tabet JY, Hittinger L, Thabut G, Jourdain P, Maison P, Tartiere JM, Solal AC (2008) Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 127: 228-232
16. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM (2002) The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8(3): 136-141
17. Aronson D, Burger AJ (2010) The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 16(7): 541-547
18. Aucella F, Guida CC, Lauriola V, Vergura M (2010) How to assess renal function in the geriatric population. J Nephrol 23(15): S46-S54
19. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
20. Manjunath G, Sarnak MJ, Levey AS (2001) Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 10: 785-792
21. James GD, Sealey JE, Alderman M, Ljungman S, Mueller FB, Pecker MS et al (1988) A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences. Am J Hypertens 1: 124-131
22. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J (2007) Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 64(6): 785-791
23. Andreev E, Koopman M, Arisz L (1999) A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med 246(3): 247-252
24. Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, O'connor C, Adams KF, Orlandi C, Gheorghiade M (2007) Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) study. J Card Fail 13(5): 360-364
25. Kazory A (2010) Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol 106(5): 694-700 (Epub 2010 Jul 23)
26. Schrier RW (2008) Blood urea nitrogen and serum creatinine. Not married in heart failure. Circ Heart Fail 1: 2-5
27. Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38: S20-S27
28. Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 5 699-707
29. Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirilä- Waris K, Sund R, Harjola VP, FINN-AKVA study group (2010) Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 31: 2791-2798
30. Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, PeuhkurinenK,Pulkki K, Nieminen MS,For the FINN-AKVAstudy group (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28: 1841-1847
31. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, NGAL meta-analysis investigator group (2009) Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 54: 1012-1024
32. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2010) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96: 1297-1302
33. Shastri S, Sarnak MJ (2010) Cardiovascular disease and CKD: Core Curriculum 2010 MS. Am J Kidn Dis 56(2): 399-417
34. Reid IA (1992) Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Phys 262(6): 763-778
35. Kielstein JT, Bode-Böger SM, Klein G, Graf S, Haller H, Fliser D (2003) Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest 33 (5) 370-375
36. Bakris GL, Re RN (1993) Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 264(6): 937-942
37. Goldsmith SR, Francis GS, Cowley AW, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1: 1385-1390
38. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275-1281
39. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8): 1004-1009
40. Winton FR (1931) The influence of venous pressure on the isolated mammalian kidney. J Physiol 72: 49-61
41. Doty JM, Saggi BH, Blocher CR, Fakhry I, Gehr T, Sica D, Sugerman HJ (2000) Effects of increased renal parenchymal pressure on renal function. J Trauma 48: 874-877
42. Maxwell MH, Breed ES, Schwartz IL (1950) Renal venous pressure in chronic congestive heart failure. J Clin Invest 29(3): 342-348
43. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Wilson Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53: 589-596
44. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9(9): 872-878
45. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51(13): 1268-1274
46. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circ 122(3): 265-272
47. Yamauchi H, Biuk-Aghai EN, Yu M, Ho HC, Chapital AD, Koss W, Takanishi DM Jr (2008) Circulating blood volume measurements correlate poorly with pulmonary artery catheter measurements. Hawaii Med J 67: 8-11
48. Drazner MH, Rame JE, Stevenson LW, Dries DL (2001) Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345: 574-581
49. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51: 1268-1274
50. Vallon V, Miracle C, Thomson S (2008) Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 10: 176-187
51. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M (1997) Plasma adenosine levels increase in patients with chronic heart failure. Circ 95: 1363-1365
52. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138: 849-855
53. Butler J, Forman DE, Abraham WT et al (2004) Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147: 331-338
54. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB (2000) Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 35(1): 56-59
55. Francis GS, Benedict C, Johnstone DE et al (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circ 82: 1724-1729
56. Tucker BJ, Blantz RC (1984) Effect of furosemide administration on glomerular and tubular dynamics in the rat. Kidney Int 26: 112-121. doi: 10.1038/ki.1984.144
57. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM (2011) NHLBI heart failure clinical research network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9): 797-805
58. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989
59. Lindenfeld J, Albert NM, Boehmer JP et al (2010) Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16: 475-539
60. Filippatos G, Parissis JT (2008) Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy? J Card Fail 14: 648-650
61. Goldsmith SR, Brandimarte F, Gheorghiade M (2010) Congestion as a therapeutic target in acute heart failure syndromes. Prog Cardiovasc Dis 52: 383-392
62. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients ospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297: 1319-1331
63. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin- 2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290(2): F273-F278
64. Gottlieb SS (2008) Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 5: 105-109
65. Slawsky MT, Givertz MM (2009) Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure. Expert Opin Pharmacother 10: 311-322
66. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002) BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circ 105: 1348-1353
67. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S (2007) The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13: 609-617
68. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC (2007) CKI-201 and CKI-202 Investigators. The effects of KW- 3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50(16): 1551-1560
69. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM, Protect Steering Committee, Investigators, and Coordinators (2008) The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 14: 631-640
70. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC (2010) PROTECT investigators and committees. Rolofylline, an adenosine a1 - receptor antagonist, in acute heart failure. N Engl J Med 363: 1419-1428
71. Gottlieb SS, Givertz MM, Metra M, Gergich K, Bird S, Jones- Burton C, Massie B, Cotter G, Ponikowski P, Weatherley B, O'Connor C, Dittrich H (2010) The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. J Card Fail 16: 714-719
72. Maskin CS, Ocken S, Chadwick B, LeJemtel TH (1985) Comparative systemic and renal effects of dopamine and angiotensin- converting enzyme inhibition with enalaprilat in patients with heart failure. Circ 72: 846-852
73. Elkayam U, Ng TM, Hatamizadeh P et al (2008) Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circ 117: 200-205
74. Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Metaanalysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142: 510-524
75. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, Skoularigis J, Westermann D, Tschöpe C, Triposkiadis F (2010) Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute decompensated heart failure (DAD-HF) trial. J Card Fail 16: 922-930
76. Kellum JA, Decker JM, Janine RN (2001) Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 29: 1526-1531
77. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP (1978) Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circ 58: 466-475
78. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I (2007) Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 21: 431-435
79. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B (2007) Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 13: 417-421
80. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M (2007) SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297(17): 1883-1891
81. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M (2002) Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541-1547
82. Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H, Cotter G (2009) Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 14: 299-307
83. Ezekowitz JA, Hernandez AF, Starling RC, Yancy CW, Massie B, Hill JA, Krum H, Diaz R, Ponikowski P, Metra M, Howlett JG, Gennevois D, O'Connor CM, Califf RM, Fonarow GC (2009) Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the acute studies of clinical effectiveness of nesiritide in subjects with decompensated heart failure (ASCEND-HF). Am Heart J 157: 219-228
84. den Uil CA, Lagrand WK, Spronk PE, van der Ent M, Jewbali LS, Brugts JJ, Ince C, Simoons ML (2009) Lowdose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail 11(4): 386-390
85. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH (2008) Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 52(3): 200-207
86. Elkayam U, Cohen G, Gogia H, Mehra A, Johnson JV, Chandraratna PA (1996) Renal vasodilatory effect of endothelial stimulation in patients with chronic congestive heart failure. J Am Coll Cardiol 28: 176-182
87. Schulz V, Bonn R, Kindler J (1979) Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure. Klin Wochenschr 57(5): 243-247
88. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351: 389-393
89. Metra M, Felker GM, Zacà V, Bugatti S, Lombardi C, Bettari L, Voors AA, Gheorghiade M, Dei Cas L (2010) Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol 144: 175-179
90. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M (2008) Fluid overload in acute heart failure: re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 10: 165-169
91. Metra M, Dei Cas L, Bristow MR (2008) The pathophysiology of acute heart failure-it is a lot about fluid accumulation. Am Heart J 155(1): 1-5
92. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G (2009) Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 14: 321-329
93. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dosefinding phase IIb study. Lancet 373: 1429-1439
94. Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M (2009) Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev 14: 309-319
95. Publication Committee for the VMAC Investigators (Vasodilatation in the Management oacknerf Acute CHF) (2002) Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287: 1531-1540
96. Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM (2009) Rationale and design of the acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). Am Heart J 157: 271-277
97. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293: 1900-1905
98. Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circ 111(12): 1487-1491
99. Kittleson M, Hurwitz S, Shah MR, Nohria A, Lewis E, Givertz M, Fang J, Jarcho J, Mudge G, StevensonLW(2003) Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 41: 2029-2035
100. Echemann M, Zannad F, Briancon S, Juillie're Y, Merte's PM, Virion JM, Villemot JP (2000) Determinants of angiotensinconverting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 139: 624-631
101. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)
102. Ronco C, Giomarelli P (2010) Current and future role of ultrafiltration in CRS. Heart Fail Rev. Oct 23. [Epub ahead of print]
103. Bourge RC, Tallaj JA (2005) Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 46: 2052-2053
104. Udani SM, Murray PT (2009) The use of renal replacement therapy in acute decompensated heart failure. Semin Dial 22(2): 173-179
105. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA (2007) UNLOAD trial investigators. J Am Coll Cardiol 49: 675-683
106. Shah RV, Givertz MM (2009) Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome. Curr Heart Fail Rep 6(3): 176-181